ZAP Surgical Raises $36 Million Led By Catalio Capital

ZAP Surgical has raised $36 million in a round led by Catalio Capital to scale its non-invasive brain surgery technology, Pulse 2.0 reports.

The figure is the headline: $36 million, with Catalio Capital — a firm known for backing commercial-stage medical device and diagnostics companies — taking the lead. That structure matters. A single lead investor stepping up at this stage usually means a deliberate bet on scaling an already-proven platform, not seed money for a concept.

What does this change for the neurosurgery market?

For practitioners, the funding signals that ZAP Surgical intends to widen deployment of its non-invasive approach to brain surgery. Non-invasive or minimally invasive platforms compete against traditional open cranial procedures, where recovery times, infection risk and hospital stays drive cost. More capital means more capacity to install systems, train surgical teams and expand the commercial footprint.

For competitors and hospital procurement teams, the message is that the radiosurgery segment is still attracting meaningful growth capital. A $36 million commitment, roughly the cost of equipping a mid-sized surgical department with several advanced systems, won't reshape the market overnight — but it extends the runway of a player pushing needle-free alternatives.

Who's behind the check

Catalio Capital led the round. The firm focuses on commercial-stage medical technology, and its lead position here indicates conviction in ZAP Surgical's path to broader adoption rather than early-stage experimentation.

Pulse 2.0, which first reported the raise, framed the deal around one goal: scaling non-invasive brain surgery. That's the operative word. This isn't a research grant; it's growth capital aimed at getting technology into more operating rooms and treatment centers.

What comes next

Watch deployment metrics: new system installations, hospital partnerships and geographic expansion. If ZAP Surgical converts this $36 million into a broader installed base over the next 12 to 24 months, it strengthens the case that non-invasive neurosurgery is moving from niche to mainstream option. For now, the capital is committed — the execution test begins.